Clinical trial · Interventional
18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology
NCT01180751CI-TRIAL-00011772unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]-Fluorodeoxyglucose | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- [18F]-Fluorodeoxyglucose
- description
- Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.
- interventionNames
- Radiation: [18F]-Fluorodeoxyglucose
Primary outcomes (1)
- measure
- To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis.
- timeFrame
- Three years
- description
- The primary outcomes of sensitivity and accuracy of 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) studies will be obtained by comparing results of the PET scan with the gold standard of histopathological diagnosis when those results are available. Comparison to correlative imaging follow-up, and assessment of efficacy based on feedback from referring physicians will be used in the absence of pathologic data.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Known or suspected primary or metastatic tumours * A neurological presentation consistent with the list of indications * 18 years of age or older of either sex * Able to provide written informed consent * Able to tolerate the physical and logistical requirements of completing a Positron Emission Tomography (PET)scan * Karnofsky score \> 60 * Women who are nursing may be included in the study if they are able to discontinue breast feeding for 12 hours Exclusion Criteria: * Age \<18 years * Pregnant women; if there is a possibility of pregnancy, bloodwork will be drawn to definitively establish pregnancy status * Women who are unwilling or unable to discontinue breast feeding for 12 hours post 18F-Fluorodeoxyglucose(FDG) administration * Subjects who are medically unstable * Subjects unwilling to provide informed consent. * Subjects who exceed the safe weight limit of the Positron Emission Tomography (PET) imaging bed or who cannot fit through the PET scanner bore
References
Publications (0)
Data not yet available
No reference posted for this study.